GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » ROA %

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) ROA % : -14.95% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Biocytogen Pharmaceuticals (Beijing) Co's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-422.5 Mil. Biocytogen Pharmaceuticals (Beijing) Co's average Total Assets over the quarter that ended in Dec. 2023 was HK$2,825.9 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's annualized ROA % for the quarter that ended in Dec. 2023 was -14.95%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's ROA % or its related term are showing as below:

HKSE:02315' s ROA % Range Over the Past 10 Years
Min: -23.95   Med: -20.51   Max: -14.31
Current: -14.31

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest ROA % was -14.31%. The lowest was -23.95%. And the median was -20.51%.

HKSE:02315's ROA % is ranked better than
70.14% of 1547 companies
in the Biotechnology industry
Industry Median: -34.69 vs HKSE:02315: -14.31

Biocytogen Pharmaceuticals (Beijing) Co ROA % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co ROA % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-18.40 -23.95 -22.61 -14.43

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial -25.73 -23.79 -25.94 -13.62 -14.95

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's ROA %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's ROA % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's ROA % falls into.



Biocytogen Pharmaceuticals (Beijing) Co ROA % Calculation

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-418.864/( (3126.614+2679.111)/ 2 )
=-418.864/2902.8625
=-14.43 %

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-422.512/( (2972.664+2679.111)/ 2 )
=-422.512/2825.8875
=-14.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-422.512/2825.8875
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-422.512 / 853.314)*(853.314 / 2825.8875)
=Net Margin %*Asset Turnover
=-49.51 %*0.302
=-14.95 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Biocytogen Pharmaceuticals (Beijing) Co ROA % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines